



Esperion Therapeutics, Inc.  
 Investor Relations Department  
 3891 Rancho Drive  
 Suite 150  
 Ann Arbor, MI 48108  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

**NASDAQ: ESPR**


|               |  |
|---------------|--|
| Last Trade:   | 38.32  |
| Trade Time:   | 4:00 PM ET<br>May 23, 2018                       |
| Change:       | -1.42 <span style="color:red">▼</span> (-3.573%) |
| Day Range     | 36.06 - 41.73                                    |
| 52-Week Range | 30.95 - 82.68                                    |
| Volume        | 3,046,651  |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- May 23, 2018  
[Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint](#)
- May 22, 2018  
[Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference](#)
- May 10, 2018  
[Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference](#)
- May 4, 2018  
[Esperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference](#)
- May 2, 2018  
[Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results](#)

## Financials [\[ View all \]](#)

- [Fourth Quarter Financial Results](#)
- Feb 20, 2018  
[Annual Report \(10-K\)](#)
- Apr 13, 2018  
[Proxy Statement \(DEF 14A\)](#)
- May 2, 2018  
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2017  
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017  
[Quarterly Report \(10-Q\)](#)